Gene therapy refers to genetic alteration of cells for preventative or therapeutic purposes. Cell-based cancer immunotherapy is the main type of cancer immunotherapy that encompasses gene therapy.
Among the cell-based cancer immunotherapies, CAR-T therapy isolates T-cells (immune cells) from a patient’s blood and, using viral vectors, genetically engineers those T-cells to produce CARs on their surface. The numbers of these engineered T-cells are greatly expanded outside the patient and then they are injected back into the patient to attack cancer cells.
CAR-T therapy has the potential to eradicate active metastatic disease in patients. To date, the best successes with CAR-T cells has been in the treatment of blood cancers.
CAR-T Therapeutics Market
- The global cancer immunotherapeutic market was estimated to be USD 62.57 billion in 2016
- Forecasted to grow at an average annual growth rate of 14.3% to reach USD 160.24 billion in 2023 (according to the Stratistics Market Research Consulting’s report published in early 2018)
- The global CAR-T cell therapeutics market in 2017 was USD 72 million
- Expected to grow into USD 8.3 billion market by 2028 after consistent growth at an average annual growth rate of 53.9%
- The largest CAR-T cell therapeutics market in the world is North America
- Asia-Pacific market is currently the third largest behind Europe
- Forecasted to grow at the fastest rate (CAGR 62.5% between 2019~2028) and replace Europe as the second largest market after North America by 2028
- In 2017, Novartis’s KYMRIAH received the world’s first FDA approval for CAR-T therapeutics
- Approved for treatment of patients up to 25 years of age with B-cell acute lymphoblastic leukemia (ALL), a pediatric blood cancer known to be difficult to treat
- Followed by Gilead’s YESCARTA, which enabled the commercial release of CAR-T therapeutics in the market
- Approved for treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma